Table 1.
Characteristics of immunosuppressive therapies for IgA nephropathy included in the network meta-analysis.
| Study | Patients | Regimens | Sample size | Age | Follow-up | ||||
|---|---|---|---|---|---|---|---|---|---|
| T | C | T (male) | C (male) | T | C | T | C | ||
| Fellstrom 2017 | e-GFR > 45 mL/min/1·73 m², proteinuria > 0.75 g/d | S | Sup. | 99 (70) | 50 (35) | 39.0 ± 12.3 | 39.0 ± 12.3 | 12 m | 12 m |
| Hogg 2006 | e-GFR ≥ 50 mL/min/1·73 m², moderate to severe proteinuria | S | Sup. | 33 (23) | 31 (20) | 24 ± 10 | 21 ± 10 | 25 m | 25 m |
| Lv 2017 | e-GFR 20 to 120 mL/min/1·73 m², proteinuria > 1 g/d | S | Sup. | 136 (86) | 126 (80) | 38.6 ± 11.5 | 38.6 ± 10.7 | 60 m | 60 m |
| Manno 2009 | e-GFR ≥ 50 mL/min/1·73 m², proteinuria ≥ 1.0 g/d | S | Sup. | 48 (33) | 49 (35) | 31.8 ± 11.3 | 34.9 ± 11.2 | 63.0 m | 57.2 m |
| Pozzi 2004 | sCr ≤ 1.5 mg/dL proteinuria, 1.0–3.5 g/d | S | Sup. | 43 (30) | 43 (31) | 38 (26–45) | 40 (29–51) | 84 m | 84 m |
| Katafuchi 2003 | sCr ≤ 1.5 mg/dL | S | Sup. | 43 (15) | 47 (22) | 33.6 ± 13.4 | 32.5 ± 10.8 | 25 m | 23 m |
| Lv 2009 | e-GFR > 30 mL/min/1·73 m², proteinuria 1.0–5.0 g/d | S | Sup. | 33 (20) | 30 (19) | 27.8 ± 8.9 | 30.43 ± 8.8 | 48 m | 48 m |
| Harmankaya 2002 | isolated hematuria, and well-preserved renal function | AZA | Sup. | 21 (15) | 22 (14) | 25 (13–42) | 27 (17–63) | 64 m | 58 m |
| Lai 1986 | nephrotic syndrome | S | Sup. | 17 | 17 | NA | NA | 38 m | 38 m |
| Shoji 2000 | sCr ≤ 1.5 mg/dL, proteinuria < 1.5 g/d | S | Sup. | 11 (5) | 8 (1) | 28.7 ± 11.2 | 33.3 ± 11.9 | 13.4 m | 13.4 m |
| Julian 1993 | sCr clearance > 25 mL/min/1·73 m² | S | Sup. | 18 | 17 | NA | NA | NA | NA |
| Liu 2014 | e-GFR > 30 mL/min/1·73 m², proteinuria > 1.0 g/d | MMF | CYC | 42 (24) | 42 (27) | 39.8 ± 3.81 | 37.4 ± 4.78 | 30.3 m | 26.9 m |
| Hou 2017 | e-GFR > 30 mL/min/1·73 m², proteinuria ≥ 1.0 g/d | MMF | S | 86 (39) | 88 (38) | 30.5 (25–37) | 32.5 (25–43) | 12 m | 12 m |
| Hogg 2015 | e-GFR ≥ 40 mL/min/1·73 m², UPCR > 0.8 g/g | MMF | Sup. | 25 (14) | 27 (18) | 31.8 ± 11.7 | 32.2 ± 13.2 | 15 m | 15 m |
| Yu 2017 | e-GFR ≥ 40 mL/min/1·73 m², UACR 0.3–3.0 g/g cr | TAC | Sup. | 18 (6) | 19 (5) | 36.8 ± 11.3 | 41.0 ± 12.6 | 57.9 m | 57.9 m |
| Kim 2013 | e-GFR ≥ 40 mL/min/1·73 m², UACR 0.3–3.0 g/g cr | TAC | Sup. | 20 (6) | 20 (6) | 36.9 ± 11.4 | 40.1 ± 12.8 | 4 m | 4 m |
| Frisch 2005 | advanced IgAN, and creatinine clearance < 80 ml/min | MMF | Sup. | 17 (16) | 15 (11) | 39 (19–72) | 37 (22–59) | 14.8 m | 18.7 m |
| Maes 2004 | proteinuria > 1.0 g/d | MMF | Sup. | 21 (16) | 13 (8) | 39 ± 11 | 43 ± 15 | 36 m | 36 m |
| Rauen 2018 | e-GFR ≥ 60 mL/min/1·73 m², proteinuria 0.75–3.5 g/d | S | Sup. | 55 (42) | 54 (47) | 41.7 ± 13.3 | 45.6 ± 11.9 | 36 m | 36 m |
| Rauen 2018 | e-GFR 30–59 mL/min/1·73 m², proteinuria 0.75–3.5 g/d | CYC + AZA | Sup. | 27 (20) | 26 (18) | 45.1 ± 12.8 | 46.0 ± 14.0 | 36 m | 36 m |
| Kamei 2011 | e-GFR ≥ 30 mL/min/1·73 m², proteinuria ≥ 1.0 g/d | AZA | Sup. | 40 (22) | 38 (29) | 12.2 ± 3.0 | 11.6 ± 2.3 | 138 m | 84 m |
| Pozzi 2010 | sCr ≤ 2.0 mg/dL, proteinuria ≥ 1.0 g/d | AZA | S | 101 (76) | 106 (75) | 34.8 (27.7–43.9) | 40.5 (30.3–51.3) | 58.8 m | 58.8 m |
| Yoshikawa 2006 | NA | AZA | S | 40 (22) | 40 (21) | 11.5 ± 3.2 | 11.1 ± 2.8 | 24 m | 24 m |
| Tang 2010 | proteinuria ≥ 1.0 g/d | MMF | Sup. | 20 (6) | 20 (8) | 42.1 ± 2.6 | 43.3 ± 2.8 | 72 m | 72 m |
| Ballardie 2002 | sCr ≥ 130 μmol/L | CYC + AZA | Sup. | 19 | 19 | 18–54 m | 18–54m | 24–72 m | 24–72 m |
Abbreviations: T treatment group, C control, S steroids, Sup. supportive care, AZA azathioprine, MMF mycophenolate mofetil, TAC tacrolimus, CYC cyclophosphamide, e-GFR estimated glomerular filtration rate, sCr creatinine, UPCR urine protein to creatinine ratio, UACR urine albumin to creatinine ratio, d day, m month, NA not available.